Key Insights from the Heart of Pharma: an exclusive CPHI Online report
CPHI Milan, held from October 8–10, 2024 in the historic Fiera Milano, celebrated its 35th edition of bringing together the pharmaceutical industry and supply chain for 3 days of collaborating and innovating. Our first CPHI Wrap-Up Report brings you the latest insight and key takeaways from the Heart of Pharma.
This report dives into 3 days of connecting with pharmaceutical experts, thought leaders, and changemakers. Exclusive interviews with CPHI Milan speakers, deep dives into conference sessions on Manufacturing 5.0, Sustainable Futures, and Next-Gen Bio, emerging pharmaceutical trends from expert roundtables, and observations from the very people who bring CPHI to life are just some of the highlights we bring back from the show floor.
In addition, the CPHI Awards and CPHI Celebration brought two new award categories, the Woman of the Year award and the Future Leader award, to highlight the amazing work of the CPHI team in platforming a diverse body of pharmaceutical professionals.
A keen focus on sustainability and diversity remains a core part of what we do at CPHI, both at our shows and online. This report will bring you unique perspectives on the pharmaceutical industry can put initiatives into action.
At CPHI, we are dedicated to connecting professionals throughout the pharmaceutical supply chain, both at our events and throughout the year with our digital marketing offerings. We are proud to have published four Trend Reports this last year, with two more coming up: the CPHI Middle East Biotech Report and our annual Pharma Trends Outlook for 2025. As we continue to grow and meet the needs of the B2B pharmaceutical sector, we hope that this CPHI Milan Post-Show Report will enable all to understand the biggest trends and conversations happening throughout the pharmaceutical industry today
Download your free Wrap-Up Report here.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...